Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function

Kim, Young‐Kook; Kim, Oh Yoen; Song, Jeong Sup

doi:10.3389/fphar.2020.01270

Cited by 58 publications

(55 citation statements)

References 218 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is also involved in metabolism and decarboxylation to form γ-aminobutyric acid, an inhibitory neurotransmitter. Disruption of neurotransmitters in the brain causes a variety of diseases, including psychosis, depression, anxiety disorder, epilepsy, and Alzheimer's disease (Duan et al 2020;Kim et al 2020), and excitatory toxicity caused by glutamate is part of an ischemic cascade that has been linked to stroke, amyotrophic lateral sclerosis, and Alzheimer's disease (Amantea and Bagetta 2017). In our study, the concentration of l-glutamic acid was higher in MMD patients than in HCs.…”

Section: Discussionmentioning

confidence: 42%

Targeted metabolomics analysis of serum amino acid profiles in patients with Moyamoya disease

Liu¹,

Jin

Wang

et al. 2021

Amino Acids

View full text Add to dashboard Cite

Amino acids are one of the main metabolites in the body, and provide energy for the body and brain. The purpose of this study is to provide a profile of amino acid changes in the serum of patients with Moyamoya disease (MMD) and identify potential disease biomarkers. In this paper, we quantitatively determined the serum amino acid metabolic profiles of 43 MMD patients and 42 healthy controls (HCs). T test, multivariate statistical analysis, and receiver operating characteristic (ROC) curve analysis were used to identify candidate markers. Thirty-nine amino acids were quantified, and 12 amino acid levels differed significantly between the MMD patients and HCs. Moreover, based on ROC curve analysis, four amino acid (l-methionine, l-glutamic acid, β-alanine and o-phosphoserine) biomarkers showed high sensitivity and specificity (AUC > 0.90), and showed the best sensitivity and specificity in MetaboAnalyst 5.0 using binary logistic regression analysis. We have provided serum amino acid metabolic profiles of MMD patients, and identified four potential biomarkers which may both provide clinicians with an objective diagnostic method for early detection of MMD and further our understanding of MMD pathogenesis.

show abstract

Section: Discussionmentioning

confidence: 42%

Targeted metabolomics analysis of serum amino acid profiles in patients with Moyamoya disease

Liu¹,

Jin

Wang

et al. 2021

Amino Acids

View full text Add to dashboard Cite

show abstract

“…Consistent with previous studies, in our present work, we found that the levels of leucine and valine were decreased in the brain tissues of the CORT group, while ACE treatment significantly reversed these effects. Moreover, tyrosine, as an aromatic amino acid, is a precursor for the synthesis of catecholamine neurotransmitters ( 51 , 52 ). It was reported that tyrosine was essential in neurotransmitters synthesis under the catalysis of tyrosine hydroxylase ( 53 , 54 ).…”

Section: Discussionmentioning

confidence: 99%

Metabolomics Analysis on Mice With Depression Ameliorated by Acupoint Catgut Embedding

et al. 2021

View full text Add to dashboard Cite

Depression is a prevalent mental disease characterized by persistent low mood, lack of pleasure, and exhaustion. Acupoint catgut embedding (ACE) is a kind of modern acupuncture treatment, which has been widely used for the treatment of a variety of neuropsychiatric diseases. To investigate the effects and underlying mechanism of ACE on depression, in this study, we applied ACE treatment at the Baihui (GV20) and Dazhui (GV14) acupoints of corticosterone (CORT)-induced depression model mice. The results showed that ACE treatment significantly attenuated the behavioral deficits of depression model mice in the open field test (OFT), elevated-plus-maze test (EPMT), tail suspension test (TST), and forced swimming test (FST). Moreover, ACE treatment reduced the serum level of adreno-cortico-tropic-hormone (ACTH), enhanced the serum levels of 5-hydroxytryptamine (5-HT), and noradrenaline (NE). Furthermore, metabolomics analysis revealed that 23 differential metabolites in the brain of depression model mice were regulated by ACE treatment for its protective effect. These findings suggested that ACE treatment ameliorated depression-related manifestations in mice with depression through the attenuation of metabolic dysfunction in brain.

show abstract

“…Increasing evidence is pointing toward an effect of GLP-1 on improving memory and cognition, and GLP-1R agonists are being investigated for the treatment of neurodegenerative disorders. Some of the neuroprotective effects are mediated by increasing neurogenesis and synaptic plasticity (reviewed by Kim et al, 2020 ). This opens an intriguing possibility that one beneficial effect that GLP-1R agonists could play in treating addiction is to open new windows of learning through neuroplasticity.…”

Section: Appetite-regulatory Peptides In Substance Use Disordermentioning

confidence: 99%

An Overview of Appetite-Regulatory Peptides in Addiction Processes; From Bench to Bed Side

2021

View full text Add to dashboard Cite

There is a substantial need for new pharmacological treatments of addiction, and appetite-regulatory peptides are implied as possible candidates. Appetite regulation is complex and involves anorexigenic hormones such as glucagon-like peptide-1 (GLP-1) and amylin, and orexigenic peptides like ghrelin and all are well-known for their effects on feeding behaviors. This overview will summarize more recent physiological aspects of these peptides, demonstrating that they modulate various aspects of addiction processes. Findings from preclinical, genetic, and experimental clinical studies exploring the association between appetite-regulatory peptides and the acute or chronic effects of addictive drugs will be introduced. Short or long-acting GLP-1 receptor agonists independently attenuate the acute rewarding properties of addictive drugs or reduce the chronic aspects of drugs. Genetic variation of the GLP-1 system is associated with alcohol use disorder. Also, the amylin pathway modulates the acute and chronic behavioral responses to addictive drugs. Ghrelin has been shown to activate reward-related behaviors. Moreover, ghrelin enhances, whereas pharmacological or genetic suppression of the ghrelin receptor attenuates the responses to various addictive drugs. Genetic studies and experimental clinical studies further support the associations between ghrelin and addiction processes. Further studies should explore the mechanisms modulating the ability of appetite-regulatory peptides to reduce addiction, and the effects of combination therapies or different diets on substance use are warranted. In summary, these studies provide evidence that appetite-regulatory peptides modulate reward and addiction processes, and deserve to be investigated as potential treatment target for addiction.

show abstract

Alleviation of Depression by Glucagon-Like Peptide 1 Through the Regulation of Neuroinflammation, Neurotransmitters, Neurogenesis, and Synaptic Function

Cited by 58 publications

References 218 publications

Targeted metabolomics analysis of serum amino acid profiles in patients with Moyamoya disease

Targeted metabolomics analysis of serum amino acid profiles in patients with Moyamoya disease

Metabolomics Analysis on Mice With Depression Ameliorated by Acupoint Catgut Embedding

An Overview of Appetite-Regulatory Peptides in Addiction Processes; From Bench to Bed Side

Contact Info

Product

Resources

About